Raia Drogasil S/A (RADL3.SA) Stock Price
Raia Drogasil S/A Price
Revenue has compounded at 24.6% per year over the past 19 years to 44.25 B BRL. Earnings per share have grown at 18.8% per year over the last 19 years. Raia Drogasil S/A's net margin stands at 2.9%, broadly stable from 3.1% several years earlier. Raia Drogasil S/A currently offers a dividend yield of about 2.06%. The payout ratio is around 59% of earnings. The dividend has grown at 7.8% per year over the past 19 years. Analysts set a median price target of 27.00 BRL, implying 26.0% above the current price. Of 20 analysts, 17 rate the stock a buy — an overall Buy consensus.
Raia Drogasil S/A stock price
Raia Drogasil S/A business model & stock analysis
Frequently asked questions about Raia Drogasil S/A
Raia Drogasil SA is a leading Brazilian retail pharmacy chain specializing in the sale of medications, personal care products, cosmetics, and healthcare items. Its business model revolves around providing a wide range of high-quality products at competitive prices through its extensive network of conveniently located stores. Raia Drogasil SA focuses on delivering exceptional customer service and offers an extensive assortment of both generic and branded products to meet the diverse needs of its customers. By leveraging its strong brand recognition and efficient supply chain, the company has successfully established itself as a trusted name in the pharmaceutical retail industry in Brazil.
Raia Drogasil SA is primarily active in the retail industry, specifically in the pharmaceutical and healthcare sectors.
The main competitors of Raia Drogasil SA in the market include major pharmacy chains such as Panvel, Droga Raia, Pague Menos, and Ultrafarma. They compete with Raia Drogasil SA in terms of market share, store network, and product offerings within the pharmaceutical retail industry. These competitors aim to attract customers with competitive prices, a wide range of products, and convenient store locations, similar to what Raia Drogasil SA offers.
Raia Drogasil SA is a prominent Brazilian retail company specializing in pharmaceutical products. Established in 2011 through the merger of Raia S.A. and Drogasil S.A., the company boasts a rich history and a solid background in the healthcare industry. Raia Drogasil SA operates an extensive network of drugstores across Brazil, providing a wide range of medicines, personal care products, beauty items, and wellness solutions. With a focus on customer satisfaction and convenient accessibility, the company has earned a strong reputation and grown into the largest retail pharmacy chain in the country. Raia Drogasil SA continues to expand its presence and actively contributes to the improvement of healthcare services in Brazil.
Raia Drogasil SA, a leading Brazilian pharmaceutical company, has achieved significant milestones over the years. The company has successfully expanded its retail network, solidifying its position as the largest chain of drugstores in Brazil. Raia Drogasil SA has also made noteworthy acquisitions, such as the purchase of Drogasil, which further enhanced its market presence. In addition, the company has consistently reported strong financial performance and steady revenue growth. Raia Drogasil SA's commitment to innovation and customer satisfaction has earned them numerous accolades, including being recognized as one of the most admired companies in Brazil.
Raia Drogasil SA is primarily present in Brazil.
Raia Drogasil SA embodies a set of core values and a corporate philosophy that define its operations and success. With a commitment to excellence and customer satisfaction, Raia Drogasil SA values integrity, professionalism, and innovation. The company strives to deliver high-quality products and services, ensuring the well-being and health of its customers. Raia Drogasil SA operates with a customer-centric approach, aiming to provide accessible healthcare solutions and personalized care. With a strong emphasis on teamwork and continuous improvement, Raia Drogasil SA fosters a supportive and dynamic work environment. These values and corporate philosophy define Raia Drogasil SA's commitment to exceptional service and its mission to be a leading player in the healthcare industry.
Analysts currently set an average price target of 27.35 BRL for the Raia Drogasil S/A stock (median: 27.00 BRL), implying +27.6 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Raia Drogasil S/A stock: 17 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Raia Drogasil S/A to generate revenue of 46.03 B BRL and earnings per share of 0.84 BRL.
Converted at the current exchange rate, the Raia Drogasil S/A share trades at 3.82 EUR (21.43 BRL).
The Raia Drogasil S/A share (RADL3.SA) is listed on 2 stock exchanges, including: B3 (São Paulo) (RADL3.SA).
Raia Drogasil SA is a leading Brazilian retail company specializing in the sale of pharmaceuticals and health products. Founded in 1905 in São Paulo, the company has built a strong presence in Brazil over the years and has become known as a reliable provider of health products and services. The business model of Raia Drogasil SA includes a range of divisions and products tailored to the needs of customers. One of the main divisions of the company is the sale of prescription and generic drugs. Here, the company offers a wide range of prescription and over-the-counter medications, as well as an extensive selection of health and wellness products. In addition to the sale of medications, Raia Drogasil SA's business model also includes other important divisions such as health insurance and pharmacies. The company provides comprehensive healthcare services ranging from prescription medications to assistance in creating nutrition plans and disease prevention. Another important component of Raia Drogasil SA's business model is its commitment to digital transformation. The company utilizes modern technologies to enhance its business processes and provide customers with a seamless and personalized experience. The company's online platform includes a wide range of products and services that can be accessed by customers anytime and anywhere. Raia Drogasil SA is also known for its wide range of private label products. The company develops and produces a variety of health and wellness products such as dietary supplements, vitamins, cosmetic products, sunscreens, and more. These products are available in all company branches and offer customers an affordable alternative to branded products. Another important aspect of Raia Drogasil SA's business model is its commitment to future growth and expansion opportunities. The company pursues an aggressive expansion strategy and plans to further expand its presence in Brazil. Key growth initiatives include opening new branches, expanding the product range, and introducing new technologies. In summary, the business model of Raia Drogasil SA is focused on meeting the growing needs of customers for health products and services. The company relies on a wide range of divisions and products, including medications, health insurance, pharmacies, digital transformation, private label products, and growth strategies, to offer its customers a comprehensive package of services. The combination of innovative products and services, a strong presence throughout Brazil, and forward-thinking leadership makes Raia Drogasil SA one of the leading healthcare companies in Brazil. Answer: Raia Drogasil SA is a leading Brazilian retail company specializing in the sale of pharmaceuticals and health products. Its business model includes divisions for medications, health insurance, pharmacies, digital transformation, private label products, and growth strategies. The company aims to meet the growing needs of customers for health products and services through innovative offerings and a strong presence throughout Brazil.
The expected revenue of Raia Drogasil S/A is 46.03 B BRL. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Raia Drogasil S/A is 1.46 B BRL. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Raia Drogasil S/A is currently 25.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Raia Drogasil S/A stock.
The price-to-sales ratio (P/S) of Raia Drogasil S/A is currently 0.81. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Raia Drogasil S/A stock.
The Eulerpool Quality Score for Raia Drogasil S/A is 8/10.
The ISIN of Raia Drogasil S/A is BRRADLACNOR0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Raia Drogasil S/A is RADL3.SA. The ticker symbol is used to trade Raia Drogasil S/A shares on the stock exchange.
Raia Drogasil S/A stock
Raia Drogasil S/A Peer Group
Raia Drogasil S/A Ticker
Raia Drogasil S/A FIGI
All fundamentals and in-depth analysis of Raia Drogasil S/A
Our stock analysis for Raia Drogasil S/A stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Raia Drogasil S/A. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.